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ABSTRACT 
 
Contrast-enhanced ultrasound or CEUS is a combination of the pharmacokinetics of contrast agents  
(or microbubbles-based ultrasound contrast agents), the signal processing of these agents and the 
contrast-specific imaging modality. 
 
One of the main objectives of this method is to gather vascular information (from large vessels to 
capillaries) in different organs or tumors by increasing the signal intensity from blood. 
 
The aim of this thesis is to evaluate the kinetic value of real time harmonic imaging contrast-enhanced 
ultrasound (CEUS) in breast tumors as a differential diagnostic tool and correlate it with prognostic 
factors in invasive breast carcinomas (Studies II and IV). 
 
Successful introduction of a new imaging method always requires studies evaluating the technical 
parameters for optimal diagnostic performance. Concerning CEUS for imaging breast tumors, the 
mode of injection and dose of injected agent can be identified among these parameters. Therefore two 
methodology studies are included in this work (Studies I and III). 
 
In Study I we evaluated which method is to prefer between bolus and continuous infusion of equal 
doses of contrast agent, in order to achieve the best technique to gather vascular information of breast 
tumors.  We observed that the qualitative assessment of the curves after bolus administration of 
contrast agent provided sharply demarcated tumors with clear visible wash-in and wash-out patterns in 
all cases. The continuous infusion with the same doses of contrast agent was not able to show a clear 
wash-in/wash out in any case.  
In Study II we investigated whether kinetic parameters of real time harmonic CEUS imaging could be 
used to differentiate between benign and malignant breast tumors. The study showed that real time 
harmonic contrast enhanced ultrasound as a kinetic tool in the breast can detect significant differences 
between benign and malignant tumors, when evaluating two main parameters: time-to-peak and 
washout ratio. Both parameters have been observed to be earlier/faster in malignancies when compared 
with benign tumors. We observed the fact that after 21 seconds the malignant tumors  tends to 
eliminate more than 50% of the total amount of contrast, while the benign tumors tends to eliminates 
less than 50 % (mean values are 69% respective 36% elimination of contrast at 21 seconds).  
In Study III we compared different doses of injected contrast agent in order to establish an optimal 
dose for the diagnosis of invasive breast cancer using real time harmonic CEUS. The results were, in 
terms of diagnostic features, that the optimal way to evaluate kinetic features of invasive breast tumors 
using real time contrast-enhanced ultrasound harmonic imaging was with a bolus injection of contrast 
agent of either 2.4 mL or 4.8 mL. 
In Study IV we correlated real time harmonic CEUS kinetic parameters with traditional and molecular 
prognostic factors in invasive breast cancer. The results were that invasive breast carcinomas exhibiting 
earlier peak enhancement and fast elimination of microbubbles contrast agent at contrast-enhanced 
ultrasound are associated with established predictors of poor prognosis. 
 
In conclusion this thesis demonstrates that kinetic parameters of real time harmonic CEUS with a bolus 
injection of either 2.4 or 4.8 mL contrast agent has potential for diagnosis, differential diagnosis and 
prognosis of invasive breast cancer tumors. 
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